Skip to main content

Drug Interactions between tivozanib and vemurafenib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

vemurafenib tivozanib

Applies to: vemurafenib and tivozanib

MONITOR: Coadministration with tivozanib may increase the plasma concentrations and therapeutic effects of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. The proposed mechanism, based on in vitro data, is decreased clearance due to inhibition of BCRP-mediated intestinal efflux by tivozanib. The clinical significance of this interaction has not been established; however, it should be taken into consideration with orally administered intestinal BCRP-sensitive substrates such as rosuvastatin.

MANAGEMENT: Caution and clinical monitoring are advised if tivozanib is prescribed with orally administered drugs that are sensitive substrates for BCRP, such as rosuvastatin. If coadministration is necessary, the manufacturer suggests separating the administration times by 2 or more hours.

References (2)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. (2021) "Product Information. Fotivda (tivozanib)." Aveo Pharmaceuticals, Inc.

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer